Immuron is a publicly traded Australian biotechnology company (ASX: IMC; OTCQX: IMROY) with proprietary and proven commercial biotechnology for producing oral immunotherapeutic products. Our commercial and pipeline products contain naturally occurring antigen targeted antibodies and other proteins, to address a range of important gastrointestinal, infectious and immune- mediated diseases.

Our antibody-containing products target diseases, including:

•    HIV/AIDS
•    Influenza
•    Gastrointestinal Mucositis related to cancer
•    Metabolic Syndrome and Type II Diabetes  (PIPELINE PRODUCTS PENDING APPROVAL OF HADASIT TRANSACTION)
•    Hepatitis C and Liver Cancer  (PIPELINE PRODUCTS PENDING APPROVAL OF HADASIT TRANSACTION)
•    Gastrointestinal infections from:
     C. difficile
     E. coli
     Rotavirus